Source: Annual Congress 2002 - Smoking cessation with special focus on COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. P. Perruchoud, J. Townsend, A. Hider, R. Sweet, C. Astbury (Basel, Switzerland; Greenford, United Kingdom). The efficacy of bupropion hydrochloride sustained release (SR) for smoking cessation is consistent in placebo-controlled studies. Eur Respir J 2002; 20: Suppl. 38, 3583

Member's Comments

No comment yet.

Related content which might interest you: A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002 A controlled trial of nortriptyline or sustained-release bupropion for smoking cessation Source: Annual Congress 2004 - Issues in tobacco control Year: 2004 Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 12s Year: 2001 Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial}, Source: Eur Respir J 2012; 40: 548-554 Year: 2012 Bupropion hydrochloride (Zyban™) is effective and well tolerated as an aid to smoking cessation - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 11s Year: 2001 Results of a Bulgarian smoking cessation trial with bupropion hydrochloride 150 mg SR Source: Eur Respir J 2001; 18: Suppl. 33, 167s Year: 2001 Effect of pre-treatment with the nicotine patch on withdrawal symptoms in smokers subsequently quitting with the nicotine patch: a double-blind randomised controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002 Short-term low-dose vs standard-dose Varenicline therapy for smoking cessation: a randomized controlled trial. Source: International Congress 2017 – Smoking cessation treatment and e-cigarettes Year: 2017 A randomised, double-blind, placebo-controlled phase 3 study investigating the efficacy of nicotine substitution (NS) on nicotine withdrawal symptoms (NWS) in hospitalised smokers (HS) Source: Annual Congress 2009 - Smoking cessation Year: 2009 Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease. 12 month follow-up phase data (ZYB40014) Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002 Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in a healthcare professionals population - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 166s Year: 2001 Efficacy and safety of a novel nicotine mouth spray in smoking cessation: A randomized, placebo-controlled, double blind, multicenter study with 52-week follow up Source: Annual Congress 2011 - Smoking cessation science Year: 2011 Randomized clinical trials with nicotine inhaler for smoking cessation Source: Eur Respir J 2003; 22: Suppl. 45, 166s Year: 2003 Efficacy of bupropion SR in a smoking cessation programme for heavy smokers: preliminary results Source: Eur Respir J 2001; 18: Suppl. 33, 167s Year: 2001 Aural electrical stimulation for smoking cessation – a double-blind, placebo controlled study Source: Eur Respir J 2005; 26: Suppl. 49, 388s Year: 2005 Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 The safety and immunogenicity of a conjugated nicotine vaccine: results from a double-blind, placebo-controlled trial in healthy smokers and non-smokers Source: Annual Congress 2004 - Update on smoking related damage and cessation Year: 2004 Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019 Predictors of long-term smoking cessation in patients with COPD: results from a randomised controlled trial Source: Eur Respir J, 49 (6) 1700561; 10.1183/13993003.00561-2017 Year: 2017